Skip to main content

Table 2 Association of incompatibility at G1m (G1m1,17- genotype) with less improvement in DAS28 at six months of treatment with anti-TNF in the discovery samples

From: Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study

     

Unadjusted

Adjusted b

Adjusted b

 

G1m genotype a

number

Baseline DAS28

ΔDAS28

Beta

P-value

Beta

P-value

All patients

G1m1,17+

92

5.9 ± 1.1

2.3 ± 1.6

0.20

0.006

0.14

0.02

 

G1m1,17-

94

5.7 ± 1.1

1.6 ± 1.5

    

INX

G1m1,17+

68

5.9 ± 1.1

2.1 ± 1.6

0.16

0.06

0.16

0.03

 

G1m1,17-

72

5.8 ± 1.1

1.6 ± 1.5

    

ADM

G1m1,17+

24

6.1 ± 1.3

2.9 ± 1.5

0.32

0.03

0.16

0.19

 

G1m1,17-

22

5.6 ± 1.4

1.9 ± 1.5

    
  1. aCarrier status; banalyses adjusted for baseline DAS28, gender and RF (and anti-TNF for All patients). ADM, adalimumab; anti-TNF, anti-tumor necrosis factor; DAS28, disease activity score in 28 joints; INX, infliximab; RF, rheumatoid factor.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us